FHTX
HealthcareFoghorn Therapeutics Inc.
$4.98
$-0.21 (-4.05%)
Jan 5, 2026
Price History (1Y)
Analysis
Foghorn Therapeutics Inc. is a biotechnology company operating in the healthcare sector, with a market capitalization of $281.63M and approximately 112 employees. The company's revenue over the trailing twelve months (TTM) totals $24.52M. The financial health of Foghorn Therapeutics Inc. indicates significant net losses, with a net income (TTM) of -$72,122,000. Additionally, the company reports negative EBITDA and free cash flow, totaling -$83,225,000 and -$10,392,500, respectively. Cash reserves amount to $180.28M, while debt stands at $22.53M. Marginally, the current ratio is 2.16. The valuation context for Foghorn Therapeutics Inc. includes a forward P/E of -4.96 and an EV/EBITDA of -1.63. Revenue growth over the year-on-year (YoY) period is reported at 4.4%. The company's price metrics, such as the beta at 3.05 and the 52-week high-low range ($6.79-$2.94), provide further context for its valuation.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $281.63M
- P/E Ratio
- N/A
- 52-Week High
- $6.79
- 52-Week Low
- $2.94
- Avg Volume
- 215.13K
- Beta
- 3.05
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 112